Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

This study has been terminated.
(SBI Biotech who provided the drug for this study has decided to no longer support the study or GNKG168.)
Sponsor:
Information provided by (Responsible Party):
Nobuko Hijiya, MD, Therapeutic Advances in Childhood Leukemia Consortium
ClinicalTrials.gov Identifier:
NCT01743807
First received: November 28, 2012
Last updated: November 22, 2015
Last verified: November 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)